The clinical evaluation of IMGN901 was initiated with a Phase I study in patients with relapsed or relapsed/refractory MM who failed at least one prior therapy and have CD56+ MM (NCT00346255) [258]. The gene discussed is NCAM1; the disease is Miyoshi myopathy.